-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $74

Benzinga·05/27/2025 12:58:14
Listen to the news
Wells Fargo analyst Tiago Fauth maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $68 to $74.